YK012 for moderate-to-severe lupus (SLE)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase Ib/II interventional trial of YK012 in adults with moderate-to-severe systemic lupus erythematosus (SLE). Phase Ib includes a dose-escalation stage to establish safety and tolerability followed by a dose-expansion stage to further evaluate safety, tolerability, and preliminary effectiveness in reducing disease activity. Phase II is designed to measure efficacy of the selected dose(s) for reducing disease activity compared with baseline while also collecting pharmacokinetic, pharmacodynamic, and immunogenicity data. Participants must have confirmed SLE with moderate-to-high activity and be on stable background therapy during the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 to 75 years (inclusive) at screening, regardless of sex
* Meet the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for SLE, with a confirmed SLE diagnosis for at least 24 weeks at screening
* Positive for anti-dsDNA antibody and/or antinuclear antibody (ANA) and/or anti-Smith antibody at screening, as determined using the local laboratory's reference ranges at the study site
* Medium to high disease activity at screening, defined as: Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score ≥7
* Receiving stable background therapy at screening
* Capable of understanding and voluntarily participating in this clinical trial, having provided written informed consent, and able to comply with scheduled visits, treatments, examinations, and other study procedures.

Exclusion Criteria:

* Known allergy to monoclonal antibodies or exogenous human immunoglobulins, or hypersensitivity to the investigational drug or any of its components
* Received any anti-CD19/CD20 therapy or any B-cell depleting agents within 6 months prior to enrollment, or B-cell stimulatory factor inhibitors within 3 months or 5 half-lives prior to enrollment
* Received TNF inhibitors, interleukin receptor blockers, other small molecules or biologics within 3 months or 5 half-lives prior to enrollment
* Received intravenous immunoglobulins or plasmapheresis within 3 months prior to enrollment
* Used traditional Chinese medicines/herbal preparations for SLE treatment containing within 2 weeks prior to enrollment
* Received live or attenuated vaccines within 1 month prior to enrollment
* Has other autoimmune diseases, inflammatory joint diseases, or skin disorders (other than SLE) that may interfere with disease activity assessment
* History of malignancy within 5 years before screening, except for cured cases with no recurrence for at least 5 years, such as basal cell or squamous cell skin cancer, cervical carcinoma in situ, ductal carcinoma in situ of breast, or papillary thyroid cancer
* Clinically significant cardiovascular/cerebrovascular diseases within 6 months prior to screening
* Presence of QTcF interval prolongation on electrocardiogram (ECG)
* Presence of poorly controlled hypertension at screening
* History of non-SLE conditions requiring oral/intravenous/intramuscular/subcutaneous corticosteroid therapy (\>2 weeks) within 6 months prior to enrollment
* Active tuberculosis at screening or untreated latent tuberculosis
* History of solid organ or bone marrow transplantation
* Presence of active infections
* Lupus nephritis requiring protocol-prohibited medications as assessed by the investigator
* Uncontrolled lupus crisis within 8 weeks prior to screening
* History of central nervous system (CNS) disorders
* Presence of clinically unstable or uncontrolled medical conditions at screening
* Presence of clinically significant abnormal laboratory test results
* Presence of active viral infections (e.g., hepatitis B, hepatitis C, HIV, or active syphilis)
* Had major surgery within 4 weeks prior to enrollment or planned during study;
* Participation in other interventional clinical trials within 4 weeks prior to enrollment
* Pregnant or lactating women, or individuals with pregnancy plans during the study and within a specified period after treatment who are unwilling to use effective contraception
* Other conditions deemed by investigators to preclude study participation.

Where it's running

• Peking Union Medical College Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Xiaofeng Zeng, Doctor of Medicine
• Email: xiaofeng.zeng@cstar.org.cn
• Phone: +86 13501069845

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-Term Extension of enpatoran for cutaneous lupus symptoms

  This extension study tests whether continuing enpatoran is safe and helpful for people with skin lupus who completed previous trials, for up to about two years.

  Recruiting Phase 3 EMD Serono · Troy, Michigan · NCT07840287

• Targeting B cells and plasma cells in lupus with a dual-action antibody

  A new injectable therapy (F182112) will be tested in adults with systemic lupus erythematosus to see if it can help by hitting both CD3 on immune cells and BCMA on B cells and plasma cells.

  Recruiting Phase 1 Shandong New Time Pharmaceutical Co., LTD · Shanghai · NCT07829614

• FT839 therapy for autoimmune diseases

  This trial tests FT839, given alone or with rituximab, to see if it is safe and can help people with certain autoimmune diseases who have not responded to other treatments.

  Recruiting Phase 1/2 Fate Therapeutics · Fullerton, California · NCT07800871

• Triple therapy with voclosporin, MMF and prednisolone in lupus nephritis

  This trial tests whether adding voclosporin to standard lupus nephritis treatment (MMF and prednisolone) early on improves kidney inflammation compared to standard therapy alone.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT07760480

• Carotid ultrasound to guide prevention of heart disease in inflammatory rheumatic diseases

  In people with inflammatory rheumatic diseases like RA, PsA, AxSpA, or SLE who are at modest cardiovascular risk, a carotid ultrasound test is used to see if they should start stronger lipid-lowering therapy to prevent heart problems.

  Recruiting at 7 sites Phase 4 Instituto de Investigación Marqués de Valdecilla · Alicante, Alicante and 16 other locations · NCT07611747

• Periodontal Health in Rare Kidney Conditions and Controls

  This study tests how common periodontitis is in people with rare kidney disorders and compares it to CKD patients and people without kidney disease.

  Recruiting Institutul Clinic Fundeni · Bucharest · NCT07575347

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.